We are live on
!
Find out more
Rafferty Asset Management Portfolio holdings
AUM
$24.6B
1-Year Est. Return
47.06%
This Fund
S&P 500
This Quarter
Est. Return
+10.97%
1 Year Est. Return
+47.06%
3 Year Est. Return
+108.18%
5 Year Est. Return
+135.84%
10 Year Est. Return
+427.13%
AUM
$19B
AUM Growth
+$4.37B
(+30%)
Cap. Flow
+$3.05B
Cap. Flow
% of AUM
16.07%
Top 10 Holdings %
Top 10 Hldgs %
39.91%
Holding
1,362
New
110
Increased
730
Reduced
452
Closed
64
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$492M |
| 2 |
iShares Russell 2000 ETF
IWM
|
+$263M |
| 3 |
Qualcomm
QCOM
|
+$143M |
| 4 |
Broadcom
AVGO
|
+$118M |
| 5 |
iShares China Large-Cap ETF
FXI
|
+$105M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
VanEck Gold Miners ETF
GDX
|
+$81.8M |
| 2 |
iShares MSCI Emerging Markets ETF
EEM
|
+$18.6M |
| 3 |
Chevron
CVX
|
+$11.9M |
| 4 |
Xtrackers Harvest CSI 300 China A-Shares ETF
ASHR
|
+$10.9M |
| 5 |
ExxonMobil
XOM
|
+$8.22M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.28% |
| 2 | Financials | 15.39% |
| 3 | Healthcare | 5.04% |
| 4 | Energy | 4.05% |
| 5 | Consumer Discretionary | 2.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
United Therapeutics
UTHR
$25.8B
| $6.04M | 0.03% |
27,964
+13,146
| +89% | +$2.58M |
|
|
GRTS
302
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $6.03M | 0.03% |
+469,239
| New | +$5.2M |
|
303
W.R. Berkley
WRB
$26.9B
| $6M | 0.03% |
163,881
+14,699
| +10% | +$521K |
|
304
Prosperity Bancshares
PB
$8.97B
| $5.98M | 0.03% |
82,692
-8,784
| -10% | -$650K |
|
305
Corning
GLW
$119B
| $5.97M | 0.03% |
160,322
+4,551
| +3% | +$170K |
|
306
Prothena Corp
PRTA
$425M
| $5.96M | 0.03% |
120,668
+79,871
| +196% | +$4.43M |
|
|
APLS
307
DELISTED
Apellis Pharmaceuticals
APLS
| $5.95M | 0.03% |
125,910
+36,711
| +41% | +$1.45M |
|
308
Sarepta Therapeutics
SRPT
$1.57B
| $5.95M | 0.03% |
66,111
+21,752
| +49% | +$1.86M |
|
309
Franklin Resources
BEN
$17.6B
| $5.91M | 0.03% |
176,400
+37,537
| +27% | +$1.24M |
|
|
SAGE
310
DELISTED
Sage Therapeutics
SAGE
| $5.9M | 0.03% |
138,756
+65,963
| +91% | +$2.76M |
|
311
Bank OZK
OZK
$5.6B
| $5.89M | 0.03% |
126,640
-1,244
| -1% | -$56.7K |
|
312
Beam Therapeutics
BEAM
$2.63B
| $5.88M | 0.03% |
73,779
+45,173
| +158% | +$3.87M |
|
|
BLUE
313
DELISTED
bluebird bio
BLUE
| $5.88M | 0.03% |
29,426
+15,972
| +119% | +$3.77M |
|
314
Starbucks
SBUX
$120B
| $5.88M | 0.03% |
50,231
+7,431
| +17% | +$838K |
|
315
Wintrust Financial
WTFC
$10.8B
| $5.87M | 0.03% |
64,625
+3,495
| +6% | +$312K |
|
316
Agios Pharmaceuticals
AGIO
$1.79B
| $5.86M | 0.03% |
178,272
+109,293
| +158% | +$4.4M |
|
317
Relay Therapeutics
RLAY
$4.1B
| $5.83M | 0.03% |
190,002
+92,906
| +96% | +$2.94M |
|
|
BPMC
318
DELISTED
Blueprint Medicines
BPMC
| $5.83M | 0.03% |
54,421
+22,836
| +72% | +$2.39M |
|
319
Exelon
EXC
$47.2B
| $5.82M | 0.03% |
141,253
-25,558
| -15% | -$963K |
|
320
O'Reilly Automotive
ORLY
$72.9B
| $5.8M | 0.03% |
123,180
-11,445
| -9% | -$495K |
|
321
Exelixis
EXEL
$13.3B
| $5.79M | 0.03% |
316,713
+160,604
| +103% | +$3.07M |
|
322
Masco
MAS
$14.1B
| $5.78M | 0.03% |
82,349
-675
| -0.8% | -$43.7K |
|
323
Ionis Pharmaceuticals
IONS
$8.6B
| $5.77M | 0.03% |
189,639
+92,902
| +96% | +$2.92M |
|
324
Annaly Capital Management
NLY
$17.1B
| $5.77M | 0.03% |
184,345
+16,555
| +10% | +$556K |
|
|
MRTX
325
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $5.74M | 0.03% |
39,131
+20,312
| +108% | +$3.15M |
|
Similar funds
CS
AF
SC
JG
Rafferty Asset Management's Q4 2021 Portfolio in Review
As of Q4 2021, Rafferty Asset Management held 1,362 positions worth $19B, up 30% from $14.6B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Rafferty Asset Management deployed $3.05B of net new capital in Q4 2021, opening 110 new positions and adding to 730 existing holdings. Its largest new stake was Aflac: 345,009 shares worth $20.1M.
By sector, the portfolio is most concentrated in Technology at 35% of assets, up from 29% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was VanEck Gold Miners ETF, an estimated $81.8M trimmed.
- Rafferty Asset Management's largest Q4 2021 buy was Aflac: 345,009 shares worth $20.1M.
- Rafferty Asset Management added most to iShares Core S&P 500 ETF in Q4 2021, an estimated $492M increase.
- Rafferty Asset Management's biggest Q4 2021 reduction was VanEck Gold Miners ETF, cutting an estimated $81.8M.
- Rafferty Asset Management fully exited CIMAREX ENERGY CO in Q4 2021, selling an estimated $8.07M.
- Rafferty Asset Management's ten largest holdings make up 40% of its $19B portfolio in Q4 2021.
- Rafferty Asset Management opened 110 new positions and closed 64 in Q4 2021.
- Rafferty Asset Management's portfolio value rose 30% quarter-over-quarter to $19B.
Based on Rafferty Asset Management's 13F filing for Q4 2021, filed 10 Feb 2022.